Melissa Paddock

Director, Senior Corporate Counsel

Solid Biosciences Inc.

• Structured, drafted and negotiated a wide range of life science agreements, aligning business objectives with corporate and legal requirements
• Managed the company’s contract function to budget, including the supervision of contracts personnel

Strategic Technology Transactions and Licensing Associate

Goodwin Procter LLP

• Represented biotech, pharmaceutical and medical device clients on complex strategic partnering, academic, and commercial transactions, which included collaboration, joint research and development, license, co-promotion, and manufacturing agreements
• Counseled life science clients in M&A transactions and financings, focusing on IP-related issues
• Drafted and negotiated settlement and license agreements
• Secondment at Novartis AG in Basel, Switzerland; drafted and advised on various license and collaboration agreements

IP Litigator

• Represented life science companies in patent infringement and related litigation, including under the Hatch-Waxman Act

IP Litigator

Kenyon & Kenyon

• Represented life science and chemical companies in various stages of patent litigation
• Drafted patent validity and infringement opinions

Chemical Engineer

Hoffman-LaRoche

• Supervised transfer of technology from Germany to a U.S. facility for the manufacture of vitamins and fine chemicals in collaboration with R&D and operations teams

• Aliada Therapeutics’ collaboration and co-development agreement with Chiesi utilizing Aliada’s proprietary blood-brain barrier crossing platform technology to development therapeutics to treat rare diseases
• Various venture-backed start-up companies’ in-licenses of foundational and other intellectual property assets from academic and research institutions
• Advised a global medical device company on the development and deployment of template license, manufacturing, and technology transfer agreements with institutions and industry partners for the pharmaceutical diagnostic business segment
• A publicly traded, clinical stage life sciences company’s grant to a European pharmaceutical company of exclusive, worldwide rights to an ALK2 inhibitor for the treatment of a rare disease, fibrodysplasia ossificans progressive, with a total deal value of over $500 million
• Joyn Bio’s collaboration with New Leaf Symbiotics to research, develop and commercialize a new class of microbes that benefits crop health and protection
• Codiak BioSciences’ $1 billion strategic collaboration with Jazz Pharmaceuticals to research, develop and commercialize exosome therapeutics to treat cancer
• Corbus Pharmaceuticals’ $200 million strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the clinical development and commercialization in Japan of an investigational drug for the treatment of two rare and serious autoimmune diseases
• A global, commercial stage biopharmaceutical company’s collaboration with a clinical stage company to research, develop and commercialize platform-based immunotherapies in oncology
• bluebird bio’s strategic collaboration with Gritstone Oncology to research, develop and commercialize oncology products using cell therapies
• bluebird bio’s $1 billion collaboration with Medigene to develop T cell receptor-based immunotherapies
• A transnational pharmaceutical company’s exclusive collaboration and license agreement to develop and commercialize pediatric products utilizing proprietary drug delivery platform
• A cardiovascular biotechnology company’s collaboration to identify novel drug targets, with an exclusive option for Tara to progress identified targets into drug discovery, clinical development and commercialization in exchange for milestone and royalty payments
• Navitor Pharmaceuticals’ development and option agreement with Supernus Pharmaceuticals for the discovery and development of mTORC1-targeted therapeutics; with a potential deal value of $475 million plus royalties